News
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Tharimmune received positive feedback from the FDA on the 505(b)(2) NDA submission for TH104 buccal film for opioid prophylaxis. Company progressing CMC plan for NDA requirements -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. announces positive preclinical results for novel oral antibody, TH023, a potential game-changer for inflammatory disease treatment. Company aims for patient-friendly administration and improved efficacy -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tharimmune, Inc. expands product pipeline with HS1940, a multispecific biologic targeting PD-1 and VEGF epitopes to enhance cancer treatment options. EpiClick™ Technology enables creation of novel therapeutics -
-
